JIGARNING NOALKOGOL YOGʻ XASTALIGI BOʻLGAN 2-TUR QANDLI DIABET BEMORLARDA GLIKEMIYANI PASAYTIRUVCHI TERAPIYANING ROLI
##article.subject##:
Qandli diabet 2 turi, NAYJK, gipoglikemik preparatlar##article.abstract##
Qandli diabet bilan og‘rigan bemorlar uchun asosiy terapevtik maqsadlardan biri maqsadli glisemik darajalarga erishishdir. NAYJK mavjud bo‘lganda, davolovchi shifokor glyukozani kamaytiradigan terapiyani tanlashda ba’zi cheklovlarga duch keladi. Glyukoza miqdorini kamaytiradigan faollikga qo‘shimcha ravishda, dorilar jigar uchun xavfsiz bo‘lishi va gepatotoksiklikga ega bo‘lmasligi kerak. Bundan tashqari, glyukozani pasaytiradigan dorilar yurak-qon tomir tizimiga xavfsizliligi isbotlagan bo‘lishi kerak, chunki 2-tur diabet va NAYJK nafaqat bir-birini og‘irlashtiradi, balki yurak-qon tomir xavfini sezilarli darajada oshiradi.
Библиографические ссылки
Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring) 2021;29:1950-60.
Cichoż-Lach H, Celiński K, Prozorow-Król B, et al. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012;18:CR735-740.
Cusi K, Orsak B, Bril F, et al. Long-term pioglitzone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Int Med. 2016;165:305-315.
EASL, EASD, EASO. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402/
Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582 – 2592.
Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care 2021;44: 399-406
Ekstedt M, Hagstrom H., Nasr P., Fredrikson M., Kechagias S., Hultcrantz R. Fibrosis Stage is the srongest predictor for disease- specific mortality in NAFLD After Up to 33 Years of Follow-Up. Hepatology. 2015;61(5):1547-1554. http://onlinelibrary.wiley.com/ doi/10.1002/hep.27368/fu
Iwasaki T., Yoneda M., Inamori M. et al. Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology. 2011. № 58. Р. 2103-2105. http://dx.doi. org/10.5754/hge11263.
Macauley M., Hollingsworth K.G., Smith F.E. et al. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab. 2015. № 100. Р. 1578-1585.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644 – 657. doi:10.1056/NEJMoa1611925
Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide. Clin Drug Investig. 2016;36(4):313 – 319
Sala-Rabanal M, Hirayama BA, Ghezzi C, et al. Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice. J Physiol. 2016;594(15):4425 – 4438. doi:10.1113/JP271904
Sattar N, Fitchetts D, Hantel S, Jyothis T, Zinman G, Zinnman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia. 2018;61(10):2155 – 2163
Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303-1307.
Yu T., Sungelo M.J., Goldberg I.J., Wang H., Eckel R.H. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins. J. Horm. Metab. Res. 2017; 49(05): 400-406 DOI: 10.1055/s-0042-110934
